Disposal Group, Not Discontinued Operation, Upfront Payment Received

No definition available.

Name:	jazz_DisposalGroupNotDiscontinuedOperationUpfrontPaymentReceived
Namespace Prefix:	jazz_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Tiered Royalty Fees Percentage, Maximum

+ References

No definition available.

+ Details

Name:	jazz_TieredRoyaltyFeesPercentageMaximum
Namespace Prefix:	jazz_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Tiered Royalty Fees Percentage, Minimum

+ References

No definition available.

+ Details

Name:	jazz_TieredRoyaltyFeesPercentageMinimum
Namespace Prefix:	jazz_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Total Potential Collaboration Payments

+ References

No definition available.

+ Details

Name:	jazz_TotalPotentialCollaborationPayments
Namespace Prefix:	jazz_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-5

+ Details

Name:	us-gaap_BusinessAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482130/360-10-45-5

+ Details

Name:	us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Indicates line item in statement of income that includes gain (loss) recognized on sale or disposal of disposal group. Excludes discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3

+ Details

Name:	us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList
Namespace Prefix:	us-gaap_
Data Type:	enum2:enumerationSetItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 55
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482640/350-30-55-40

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 928
-SubTopic 340
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478859/928-340-50-1

+ Details

Name:	us-gaap_FiniteLivedIntangibleAssetsGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jazz_SunosiMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=jazz_RedxPharmaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=jazz_UpfrontPaymentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=jazz_PotentialMilestonePaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=jazz_AutifonyTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=jazz_ZymeworksMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=jazz_OneTimePaymentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=jazz_MilestonePaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=jazz_SumitomoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=jazz_WerewolfMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=jazz_AxsomeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborations and Disposition (Details) - USD ($) $ in Thousands	1 Months Ended				12 Months Ended
	Feb. 29, 2024	Nov. 30, 2023	Sep. 30, 2023	Oct. 31, 2022	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Nov. 30, 2024	May 31, 2022
Business Acquisition [Line Items]
Acquired in-process research and development					$ 10,000	$ 19,000	$ 444,148
Upfront and milestone payment values					7,713,412	$ 7,800,209
Disposal group, not discontinued operation, gain (loss) on disposal, statement of income or comprehensive income [Extensible Enumeration]							Selling, general and administrative
Disposal Group, Held-for-sale, Not Discontinued Operations \| Sunosi
Business Acquisition [Line Items]
Loss on disposal							$ 40,800
Redx Pharma \| Upfront Payment
Business Acquisition [Line Items]
Acquired in-process research and development	$ 10,000
Redx Pharma \| Potential Milestone Payment
Business Acquisition [Line Items]
Upfront and milestone payment values					870,000
Autifony Therapeutics \| Upfront Payment
Business Acquisition [Line Items]
Acquired in-process research and development		$ 18,000
Autifony Therapeutics \| Potential Milestone Payment
Business Acquisition [Line Items]
Upfront and milestone payment values					$ 752,500
Zymeworks
Business Acquisition [Line Items]
Acquired in-process research and development							375,000
Tiered royalty fees percentage, minimum					10.00%
Tiered royalty fees percentage, maximum					20.00%
Zymeworks \| Upfront Payment
Business Acquisition [Line Items]
Acquired in-process research and development				$ 50,000
Zymeworks \| Potential Milestone Payment
Business Acquisition [Line Items]
Total potential collaboration payments					$ 1,800,000
Zymeworks \| One-Time Payments
Business Acquisition [Line Items]
Acquired in-process research and development				$ 325,000
Zymeworks \| Milestone Payment
Business Acquisition [Line Items]
Upfront and milestone payment values					1,400,000			$ 25,000
Sumitomo \| Upfront Payment
Business Acquisition [Line Items]
Acquired in-process research and development							50,000
Sumitomo \| Potential Milestone Payment
Business Acquisition [Line Items]
Upfront and milestone payment values					1,090,000
Werewolf \| Upfront Payment
Business Acquisition [Line Items]
Acquired in-process research and development							$ 15,000
Werewolf \| Potential Milestone Payment
Business Acquisition [Line Items]
Upfront and milestone payment values					$ 1,260,000
Werewolf \| Milestone Payment
Business Acquisition [Line Items]
Acquired in-process research and development			$ 5,000
Axsome \| Disposal Group, Held-for-sale, Not Discontinued Operations \| Sunosi
Business Acquisition [Line Items]
Upfront payment received									$ 53,000